Clinical Trial Finder

Inclusion Criteria:

• - Patients with a histologically confirmed diagnosis of head and neck squamous cell carcinoma OR metastatic cutaneous or mucosal melanoma measurable per RECIST.

• - Progressive squamous cell cancer of the head and neck or metastatic melanoma since prior systemic treatment and who are: 1.

Not candidates for known curative intent therapy. 2. Progressed following at least one prior systemic therapy. 3. Have advanced melanoma unresectable stage III or stage

• IV. 4.

Have advanced head and neck recurrent or metastatic disease.

• - Have no more than 3 brain metastases.

Note: If lesions are symptomatic or ≥ 1 cm each, these lesions must have been treated and stable for 3 months for the patient to be eligible.

• - Life expectancy of greater than 3 months.

• - ECOG Performance Status of 0 or 1.

• - Adequate organ and marrow function.

• - Seronegative for HIV antibody.

• - Seronegative for Hepatitis B antigen, or Hepatitis C antibody or antigen.

• - More than four weeks has elapsed since the patient received any prior systemic therapy at the time of enrollment.

• - Patient has stable or progressing disease after at least one prior treatment.

• - Six weeks or more have elapsed since the patient received any prior anti-CTLA4 antibody therapy.

Exclusion Criteria:

• - Currently using investigational agents.

• - Had prior cell transfer therapy which included a non-myeloablative or myeloablative chemotherapy regimen.

• - Patient is a female of child-bearing potential who is pregnant or breastfeeding.

• - Patient requires immune suppressive therapy including but not limited to greater than physiologic steroid replacement.

• - Active systemic infections, coagulation disorders or other active major medical illnesses of the cardiovascular, respiratory or immune system, as evidenced by a positive stress thallium or comparable test, myocardial infarction, cardiac arrhythmias, obstructive or restrictive pulmonary disease.

• - Patient has any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease and AIDS).

• - Patient has opportunistic infections.

• - Patient has a history of coronary revascularization or ischemic symptoms.

• - Patients with clinically significant atrial and/or ventricular arrhythmias including but not limited to: atrial fibrillation, ventricular tachycardia, second or third degree heart block.

Arms

Experimental: melanoma

Experimental: head and neck cancer

Interventions

Biological: - Autologous Tumor Infiltrating Lymphocytes

Autologous TILs

Biological: - High-Dose Interleukin 2

720,000 IU/kg every 8 hours for up to 15 doses